| Literature DB >> 33204180 |
Panitha Jindahra1, Angsana Phuphuakrat2, Thanapol Tangjaisanong3, Sukanya Siriyotha4, Tanyatuth Padungkiatsagul5, Kavin Vanikieti5, Pisit Preechawat5, Anuchit Poonyathalang5, Somnuek Sungkanuparph6, Teeratorn Pulkes1, Supoch Tunlayadechanont1.
Abstract
INTRODUCTION: Acute optic neuritis (ON) has been increasingly reported in patients infected with human immunodeficiency virus (HIV). We aimed to describe clinical characteristics of HIV-infected patients with ON.Entities:
Keywords: CD4 cell count; acquired immune deficiency syndrome; human immunodeficiency virus; immune reconstitution inflammatory syndrome; optic neuritis
Year: 2020 PMID: 33204180 PMCID: PMC7667592 DOI: 10.2147/IMCRJ.S267867
Source DB: PubMed Journal: Int Med Case Rep J ISSN: 1179-142X
Patient Demographic Data
| Cases | Age | Sex | Opportunistic Infections | Number of Affected Eyes | Initial VA (RE, LE) | Optic Disc Appearance | Anterior Chambers | Visual Field Defects | Follow-Up VA (RE, LE) | Drugs | CD4 Counts During ON Episode |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Infectious ON Group | |||||||||||
| 1 | 38 | Male | Cryptococcal meningitis | 2 | 1.7, 1.7 | Swollen discs with hemorrhage | No inflammation in both eyes | Bilateral generalized depressed field | 3, 1.7 | Amphotericin B, fluconazole | 44 |
| 2 | 30 | Male | Cryptococcal meningitis | 2 | 1.7, 2 | Swollen discs with hemorrhage | No inflammation in both eyes | Bilateral generalized depressed field | 1.7, 2 | Amphotericin B, fluconazole | 25 |
| 3 | 39 | Female | Cryptococcal meningitis | 2 | 0.88, 0.3 | Swollen discs with hemorrhage | No inflammation in both eyes | Bilateral generalized depressed field | 1.7, 1.7 | Amphotericin B, fluconazole | 29 |
| 4 | 20 | Male | Cryptococcal meningitis | 2 | 1.7, 2.3 | Swollen both discs, hemorrhage in the right eye | No inflammation in both eyes | Bilateral generalized depressed field | 0.18, 1.7 | Amphotericin B, fluconazole, optic nerve sheath fenestration in the left eye | 44 |
| 5 | 37 | Male | Neuro-syphilis | 1 | 0, 0.88 | Swollen left disc with hemorrhage | Inflammation in the left eye | Generalized depressed field | 0, 0 | Penicillin G sodium | 158 |
| 6 | 38 | Male | Neuro-syphilis | 2 | 0.4, 0.3 | Swollen discs without hemorrhage | No inflammation in both eyes | Bilateral peripheral restriction | 0.1, 0 | Penicillin G sodium | 12 |
| Non-infectious ON group | |||||||||||
| 7 | 51 | Male | No infection | 1 | 0.1, 0.7 | Normal optic discs | No inflammation in both eyes | Central scotoma | 0.1, 0.3 | Intravenous methylprednisolone 1 gram once daily for 3 days | 89 |
| 8 | 49 | Female | No infection | 2 | 1.3, 1.7 | Normal optic discs | No inflammation in both eyes | Central scotoma in the right, generalized depressed field in the left | 0.1, 0.1 | Intravenous methylprednisolone 1 gram once daily for 5 days | 107 |
| 9 | 45 | Male | No infection | 1 | 0, 0.4 | Swollen left disc with hemorrhage | No inflammation in both eyes | Peripheral restriction | 0.1, 0 | Intravenous methylprednisolone 1 gram once daily for 3 days | 208 |
| 10 | 32 | Female | No infection | 1 | 1.7, 0 | Normal optic discs | No inflammation in both eyes | Generalized depressed field | 0.1, 0 | Intravenous methylprednisolone 1 gram once daily for 5 days | 371 |
Figure 1A 39-year-old HIV-infected female presented with bilateral optic neuritis and cryptococcal meningitis. (A) axial contrast-enhanced T1-weighted images with fat suppression showed enhancement of both optic nerves at the intraorbital, intracanal, and intracranial segments (arrows); (B) coronal contrast-enhanced T1-weighted images with fat suppression showed enhancement of both optic nerves at the intraorbital segments (arrows); (C) coronal contrast-enhanced T1-weighted images with fat suppression showed enhancement of both optic nerves at the intracranial segments (arrows); (D) Axial T2-weighted images with fat suppression showed signal hyperintensity at both cerebral peduncles (arrows) and intraorbital optic nerves; (E) Coronal T2-weighted images with fat suppression showed intracranial optic nerve signal hyperintensity (arrows); (F) axial fluid-attenuation inversion recovery images of the brain showed signal hyperintensity at the genu and posterior limb of left internal capsule (arrowheads); (G) axial contrast-enhanced T1-weighted images of the brain showed abnormal enhancement at the genu and posterior limb of left internal capsule (arrowheads); (H) axial contrast-enhanced T1-weighted images of the brain showed mild leptomeningeal enhancement, suggestive of meningitis.
Figure 2A 49-year-old HIV-infected female, who received antiretroviral therapy with well-controlled HIV viral load, presented with bilateral optic neuritis (immune reconstitution inflammatory syndrome-associated optic neuritis). (A) axial contrast-enhanced T1-weighted images with fat suppression showed enhancement of both optic nerves at the intracanal and intracranial segments (arrows); (B) coronal contrast-enhanced T1-weighted images with fat suppression showed enhancement of both optic nerves at the intraorbital segments (arrows); (C) coronal contrast-enhanced T1-weighted images with fat suppression showed enhancement of both optic nerves at the intracranial segments (arrows); (D) coronal contrast-enhanced T1-weighted images with fat suppression showed enhancement of the chiasm (arrow).
Figure 3Diagram showing individual trajectories of the CD4 cell count over time in the non-infectious (immune-mediated) ON group. Each color line and the corresponding arrow color represents each patient. Small arrows represent acute ON attacks. Black dots represent antiretroviral initiation. Black rings represent steroid treatments. Three patients (blue, light blue, and purple lines) successfully achieved HIV infection control. They developed acute ON while their CD4 cell counts were rising, and HIV viral load became undetectable. A female patient (black line), who did not receive ART, developed NMOSD-ON while her CD4 cell counts were 371 cells/µL. All the patients in this group did not have opportunistic infections and were responsive to corticosteroid treatments.